EGFR tyrosine kinase inhibitors (TKIs ... plus stereotactic ablative radiation (SABR). The trial included 43 patients with disease response to osimertinib who also had persisting lesions; patients ...

Among those patients with EGFR mutations, the ORR was 43.6%. Median duration of response was 7 months. More to Learn Velcheti said that more data are needed to fully understand when to continue ...

The FDA cleared the investigational new drug application for ALX2004, with phase 1 trials expected to begin in mid-2025 for ...

Tagrisso is associated with positive outcomes among patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer ...

Objective Many societies recommend using estimated glomerular filtration rate (eGFR) rather than serum creatinine (sCr) to determine metformin eligibility. We examined the potential impact of ...

Results from multiple clinical trials showed that Tagrisso demonstrated survival benefits in EGFR-mutated non-small cell lung cancer ... module showed an ORR of 43% in the 6 mg group and 36% in the 4 ...

Among 117 patients with EGFR-mutated NSCLC who had tried a median of three prior lines of therapy, Datroway alone achieved an ORR of 43% in the analysis, with the responses lasting for a median of ...